Post-transplant Autologous Cytokine-induced Killer (CIK) Cells for Treatment of High Risk Hematologic Malignancies

Part of paid clinical trials in Stanford, California.

Sponsor
Sally Arai
Study ID
NCT00477035
Phase
PHASE1
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • CIK cells — DRUG
    2x10e8 cells/kg
  • etoposide — DRUG
    60 mg/kg
  • bcnu — DRUG
    15 mg/kg
  • cyclophosphamide — DRUG
    100 mg/kg
  • gemcitabine — DRUG
    1250 mg/m2
  • vinorelbine — DRUG
    30 mg/m2
  • melphalan — DRUG
    200 mg/m2

Study Details

The purpose of the study is to conduct a phase I study of adoptive immunotherapy with autologous, ex-vivo expanded cytokine-induced killer (CIK) cells to reduce the relapse rate in autologous stem cell transplant patients with high-risk hematologic malignancies.

Key Dates

Start date
May 31, 2006
Status verified
Jan 2017
Primary completion
Mar 31, 2011
Completion
Mar 31, 2011

Study Design

Enrollment
22 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION

Arms

  • Experimental: Autologous Cytokine-induced Killer Cells

Primary Outcome Measure

To document the toxicities of infusion of autologous CIK cells [ Time Frame: Day 42 post autologous stem cell transplant ]

Locations (1)

FacilityCityStateZIPSite coordinators
Stanford University School of MedicineStanfordCalifornia94305-

Find similar trials in Stanford, CA

By condition
Leukemia (other)Multiple myeloma
By specialty
OncologyBlood cancer
By research site
Stanford University School of Medicine· Stanford, CA

Related Studies